Alliancebernstein L.P. Viridian Therapeutics, Inc.\De Transaction History
Alliancebernstein L.P.
- $280 Billion
- Q4 2024
A detailed history of Alliancebernstein L.P. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Alliancebernstein L.P. holds 2,286,994 shares of VRDN stock, worth $37.2 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,286,994
Previous 2,202,739
3.83%
Holding current value
$37.2 Million
Previous $50.1 Million
12.51%
% of portfolio
0.02%
Previous 0.02%
Shares
10 transactions
Others Institutions Holding VRDN
# of Institutions
200Shares Held
79.4MCall Options Held
477KPut Options Held
917K-
Black Rock Inc. New York, NY4.77MShares$77.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$74.8 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$73.6 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$63.2 Million12.28% of portfolio
-
State Street Corp Boston, MA3.52MShares$57.3 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $649M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...